Comparing the effects of tofogliflozin and pioglitazone in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus (ToPiND study): a randomized prospective open-label controlled trial

INTRODUCTION: The treatment of diabetes has a significant impact on the pathogenesis of non-alcoholic fatty liver disease (NAFLD). We compared the effectiveness of tofogliflozin, a selective sodium-glucose cotransporter 2 inhibitor, and pioglitazone for the treatment of NAFLD patients with type 2 di...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoneda, Masato, Honda, Yasushi, Ogawa, Yuji, Kessoku, Takaomi, Kobayashi, Takashi, Imajo, Kento, Ozaki, Anna, Nogami, Asako, Taguri, Masataka, Yamanaka, Takeharu, Kirikoshi, Hiroyuki, Iwasaki, Tomoyuki, Kurihashi, Takeo, Saito, Satoru, Nakajima, Atsushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888333/
https://www.ncbi.nlm.nih.gov/pubmed/33593749
http://dx.doi.org/10.1136/bmjdrc-2020-001990

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7888333/
https://www.ncbi.nlm.nih.gov/pubmed/33593749
http://dx.doi.org/10.1136/bmjdrc-2020-001990

Ejemplares similares